Triple therapy before surgery for liver cancer
Part of Cancer clinical trials.
This trial tests whether a combination of three drugs given before surgery can help shrink liver cancer and improve outcomes for patients whose tumors can be removed. It is for people with intermediate-stage liver cancer that is still operable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your liver function is good (Child-Pugh class A).
- Your cancer is stage A or B according to BCLC staging, and your tumor(s) are larger than 5 cm or there are multiple tumors.
- You have not had any prior cancer treatment like surgery, chemotherapy, targeted therapy, or immunotherapy.
- You are willing to use contraception during and for 6 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This study tests a combination of treatments to shrink liver cancer that cannot be removed with surgery at first. The goal is to make the tumor small enough for surgery or to disappear completely, and then either have surgery or continue the treatment.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Hear when a new Resectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.